What discharge insulin regimen should be used for a patient with a random glucose of 300 mg/dL, normal anion gap and bicarbonate, who is currently on insulin glargine (Lantus) 25 units daily plus a medium‑strength sliding‑scale insulin?

Discharge Insulin Regimen for Euglycemic Hyperglycemia with Normal Anion Gap

Increase insulin glargine (Lantus) to 30–35 units once daily at bedtime and add rapid-acting insulin 4–6 units before each of the three largest meals, while discontinuing sliding-scale insulin as the sole regimen. This patient's random glucose of 300 mg/dL with normal anion gap and bicarbonate indicates inadequate basal coverage and the need for scheduled prandial insulin rather than reactive correction doses alone. 1

---

Immediate Medication Adjustments

Basal Insulin Escalation

• Increase Lantus from 25 units to 30–35 units once daily (approximately 4–6 unit increment) to address persistent fasting and between-meal hyperglycemia. 1
• The American Diabetes Association recommends increasing basal insulin by 4 units every 3 days when fasting or random glucose remains ≥180 mg/dL until reaching the target range of 80–130 mg/dL. 1
• A glucose of 300 mg/dL signals complete inadequacy of the current basal dose and warrants immediate escalation rather than waiting for outpatient titration. 1

Initiate Scheduled Prandial Insulin

• Start rapid-acting insulin (lispro, aspart, or glulisine) at 4–6 units before each of the three largest meals to cover meal-related glucose excursions that sliding-scale insulin cannot prevent. 1
• Administer prandial insulin 0–15 minutes before meals (ideally immediately before eating) for optimal post-prandial control. 1
• An alternative starting dose is 10% of the current basal dose (approximately 3 units per meal if using 30 units basal), though 4–6 units is more appropriate given the severity of hyperglycemia. 1

Discontinue Sliding-Scale Insulin as Monotherapy

• Immediately discontinue the medium sliding-scale regimen as the sole insulin therapy because major diabetes guidelines condemn this reactive approach. 1, 2
• Sliding-scale insulin treats hyperglycemia only after it occurs, producing dangerous glucose fluctuations and achieving target glucose in only ≈38% of patients versus ≈68% with scheduled basal-bolus therapy. 1, 2
• Correction doses may still be used as supplements to the scheduled basal-bolus regimen (e.g., 2 units for pre-meal glucose >250 mg/dL, 4 units for >350 mg/dL), but never as a replacement for scheduled insulin. 1, 2

---

Rationale for Basal-Bolus Therapy

Why Basal Insulin Alone Is Insufficient

• A random glucose of 300 mg/dL indicates both inadequate fasting control and uncontrolled post-prandial hyperglycemia, necessitating combined basal and mealtime insulin. 1
• When basal insulin approaches 0.5 units/kg/day (approximately 35–40 units for most adults) without achieving targets, adding prandial insulin becomes more appropriate than continuing basal escalation alone to avoid "over-basalization." 1
• Clinical signs of over-basalization include basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia episodes, and high glucose variability. 1

Evidence Supporting Basal-Bolus Over Sliding-Scale

• Properly implemented basal-bolus therapy enables ≈68% of patients to achieve mean glucose <140 mg/dL, compared with ≈38% using sliding-scale insulin alone. 1, 2
• Basal-bolus regimens do not increase overall hypoglycemia incidence when titrated according to protocol, unlike inadequate sliding-scale approaches. 1, 2
• Treatment failure (≥2 consecutive glucose readings >240 mg/dL) occurs in ≈19% of patients on sliding-scale alone versus 0–2% on basal-bolus therapy. 2

---

Titration Protocols for Outpatient Follow-Up

Basal Insulin (Lantus) Titration

• Increase by 2 units every 3 days if fasting glucose is 140–179 mg/dL. 1
• Increase by 4 units every 3 days if fasting glucose is ≥180 mg/dL. 1
• Target fasting glucose: 80–130 mg/dL. 1
• Stop basal escalation when the dose approaches 0.5 units/kg/day (approximately 35–50 units for most adults) without achieving targets; instead, intensify prandial insulin. 1

Prandial Insulin Titration

• Increase each meal dose by 1–2 units (≈10–15%) every 3 days based on the 2-hour post-prandial glucose reading. 1
• Target post-prandial glucose: <180 mg/dL. 1
• If hypoglycemia occurs without an obvious cause, reduce the implicated dose by 10–20% immediately. 1

Correction Insulin Protocol (Adjunct Only)

• Add 2 units of rapid-acting insulin for pre-meal glucose >250 mg/dL. 1
• Add 4 units for pre-meal glucose >350 mg/dL. 1
• Correction doses must supplement—not replace—scheduled basal and prandial insulin. 1, 2

---

Monitoring Requirements

Daily Glucose Checks

• Fasting glucose daily to guide basal insulin adjustments. 1
• Pre-meal glucose before each meal to calculate correction doses. 1
• 2-hour post-prandial glucose after each meal to assess prandial adequacy. 1
• Bedtime glucose to evaluate overall daily pattern. 1

Follow-Up Schedule

• 1–2 weeks post-discharge: primary-care or endocrinology visit to assess glucose control and medication adherence. 1
• Monthly visits until HbA1c falls below 9%; thereafter every 3 months. 1
• Urgent endocrinology referral required for HbA1c >9% with unstable glucose. 1

---

Expected Clinical Outcomes

Glycemic Control

• With appropriately weight-based basal-bolus therapy, ≈68% of patients achieve mean glucose <140 mg/dL, compared with ≈38% on sliding-scale alone. 1, 2
• An HbA1c reduction of 2–3% is achievable within 3–6 months with intensive insulin titration. 1

Safety Profile

• Properly implemented basal-bolus regimens do not increase hypoglycemia risk relative to under-dosed insulin. 1, 2
• The recommended target glucose range for most adults is 140–180 mg/dL during hospitalization and 80–130 mg/dL fasting as an outpatient. 1

---

Critical Pitfalls to Avoid

Do Not Continue Sliding-Scale Monotherapy

• Never discharge a patient on sliding-scale insulin alone when glucose values repeatedly exceed 180 mg/dL; this strategy is inferior and unsafe. 1, 2
• Sliding-scale insulin as monotherapy is explicitly condemned by the American Diabetes Association and all major diabetes guideline societies. 1, 2

Do Not Delay Prandial Insulin Addition

• Do not delay adding prandial insulin when random glucose is 300 mg/dL, as this clearly indicates the need for both basal and mealtime coverage. 1
• Blood glucose in the 300 mg/dL range likely reflects both inadequate basal coverage and postprandial excursions requiring mealtime insulin. 1

Do Not Over-Escalate Basal Insulin Alone

• Avoid continuing basal insulin escalation beyond 0.5–1.0 units/kg/day without addressing post-prandial hyperglycemia, as this leads to over-basalization with increased hypoglycemia risk and suboptimal control. 1
• When basal insulin exceeds 0.5 units/kg/day without achieving targets, adding prandial insulin is more appropriate than further basal increases. 1

Do Not Use Rapid-Acting Insulin at Bedtime Alone

• Never administer rapid-acting insulin at bedtime as a sole correction dose, as this markedly raises the risk of nocturnal hypoglycemia. 1, 2

---

Hypoglycemia Management

Immediate Treatment

• Treat any glucose <70 mg/dL promptly with 15 g of fast-acting carbohydrate (e.g., 4 glucose tablets or 4 oz juice), recheck in 15 minutes, and repeat if needed. 1
• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% before the next administration. 1

Patient Education Essentials

• Hypoglycemia recognition and treatment: symptoms include shakiness, sweating, confusion, rapid heartbeat; treat with 15 g carbohydrate when glucose <70 mg/dL. 1
• Proper insulin injection technique and site rotation to prevent lipohypertrophy. 1
• Sick-day management: continue insulin even if not eating, check glucose every 4 hours, maintain hydration. 1
• Glucose monitoring: at least four daily measurements (fasting, pre-meal, bedtime) during titration. 1

---

Special Considerations

Euglycemic DKA Risk Assessment

• Although this patient has normal anion gap and bicarbonate, ruling out euglycemic diabetic ketoacidosis (DKA) is prudent given the severe hyperglycemia. 3, 4, 5
• Check serum β-hydroxybutyrate if the patient has nausea, vomiting, abdominal pain, or altered mental status; a level ≥1.0 mmol/L warrants further evaluation. 3
• If ketones are present, do not discontinue insulin; instead, add dextrose to IV fluids while maintaining insulin infusion to clear ketones. 3

Metformin Optimization

• Continue or up-titrate metformin to at least 1000 mg twice daily (2000 mg total) unless contraindicated; this reduces total insulin requirements by 20–30% and yields superior glycemic control. 1
• Metformin should not be discontinued during insulin intensification unless specific contraindications exist (e.g., renal impairment, acute illness). 1

Alternative to Prandial Insulin: GLP-1 Receptor Agonist

• If basal insulin exceeds 0.5 units/kg/day without achieving targets, consider adding a GLP-1 receptor agonist (e.g., semaglutide) instead of prandial insulin; this approach offers comparable post-prandial control with lower hypoglycemia risk and weight loss rather than weight gain. 1